febuxostat (Rx)

Brand and Other Names:Uloric
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet

  • 40mg
  • 80mg
more...

Chronic Gout

Indicated for chronic management of hyperuricemia in patients with gout who have an inadequate response to optimal allopurinol therapy, who are intolerant to allopurinol, or for whom treatment is not advisable

Initial dose: 40 mg PO qDay

May increase to 80 mg PO qDay after 2 wk if serum uric acid <6 mg/dL is not achieved

Dosage Modifications

Renal impairment

  • Mild to moderate (CrCl 30-89 mL/min): No dosage adjustment necessary
  • Severe (CrCl <30 mL/min): Not to exceed 40 mg/day

Hepatic impairment

  • Mild to moderate (Child-Pugh class A or B): Dosage adjustment not necessary
  • Severe (Child-Pugh class C): Data not available; use with caution

Prophylaxis for gout flares during treatment

  • Upon initiation, recommend for flare prophylaxis with a nonsteroidal anti-inflammatory drug (NSAID) or colchicine
  • Prophylactic therapy may be beneficial for up to 6 months
  • If a gout flare occurs, managed gout flare concurrently; treatment does not need to be discontinued

Dosing Considerations

Limitation of use: Not recommended for the treatment of asymptomatic hyperuricemia

Perform serum uric acid level as early as 2 weeks after initiating therapy

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and febuxostat

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            1-10%

            Liver function abnormalities (4.6-6.6%)

            Rash (0.5-1.6%)

            Nausea (1.1-1.3%)

            Arthralgia (0.7-1.1%)

            >1%

            Blood and lymphatic system disorders: Anemia, idiopathic thrombocytopenic purpura, leukocytosis/leukopenia, neutropenia, pancytopenia, splenomegaly, thrombocytopenia

            Cardiac disorders: Angina pectoris, atrial fibrillation/flutter, cardiac murmur, ECG abnormal, palpitations, sinus bradycardia, tachycardia

            Ear and labyrinth disorders: Deafness, tinnitus, vertigo

            Eye disorders: Vision blurred

            Gastrointestinal disorders: Abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, hematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting

            General disorders and administration site conditions: Asthenia, chest pain/discomfort, edema, fatigue, feeling abnormal, gait disturbance, influenza-like symptoms, mass, pain, thirst

            Hepatobiliary disorders: Cholelithiasis/cholecystitis, hepatic steatosis, hepatitis, hepatomegaly

            Immune system disorder: Hypersensitivity

            Infections and infestations: Herpes zoster

            Procedural complications: Contusion

            Metabolism and nutrition disorders: Anorexia, appetite decreased/increased, dehydration, diabetes mellitus, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypokalemia, weight decreased/increased

            Musculoskeletal and connective tissue disorders: Arthritis, joint stiffness, joint swelling, muscle spasms/twitching/tightness/weakness, musculoskeletal pain/stiffness, myalgia

            Nervous system disorders: Altered taste, balance disorder, cerebrovascular accident, Guillain-Barré syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor

            Psychiatric disorders: Agitation, anxiety, depression, insomnia, irritability, libido decreased, nervousness, panic attack, personality change

            Renal and urinary disorders: Hematuria, nephrolithiasis, pollakiuria, proteinuria, renal failure, renal insufficiency, urgency, incontinence

            Reproductive system and breast changes: Breast pain, erectile dysfunction, gynecomastia

            Respiratory, thoracic and mediastinal disorders: Bronchitis, cough, dyspnea, epistaxis, nasal dryness, paranasal sinus hypersecretion, pharyngeal edema, respiratory tract congestion, sneezing, throat irritation, upper respiratory tract infection

            Skin and subcutaneous tissue disorders: Alopecia, angio edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis, peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria

            Vascular disorders: Flushing, hot flush, hypertension, hypotension

            Laboratory parameters: Activated partial thromboplastin time prolonged, creatine increased, bicarbonate decreased, sodium increased, EEG abnormal, glucose increased, cholesterol increased, triglycerides increased, amylase increased, potassium increased, TSH increased, platelet count decreased, hematocrit decreased, hemoglobin decreased, MCV increased, RBC decreased, creatinine increased, blood urea increased, BUN/creatinine ratio increased, creatine phosphokinase increased, alkaline phosphatase increased, LDH increased, PSA increased, urine output increased/decreased, lymphocyte count decreased, neutrophil count decreased, WBC increased/decreased, coagulation test abnormal, low density lipoprotein increased, prothrombin time prolonged, urinary casts, urine positive for white blood cells and protein

            Postmarketing Reports

            Immunologic: Anaphylaxis, anaphylactic reaction

            Musculoskeletal: Rhabdomyolysis

            Hepatobiliary: Hepatic failure (some fatal), jaundice, serious cases of abnormal LFT results, liver disorders

            Psychiatric: Psychotic behavior, including aggressive thoughts

            Renal and urinary: Tubulointerstitial nephritis

            Dermatologic: Generalized rash, Stevens-Johnson syndrome, hypersensitivity skin reactions, drug reaction with eosinophilia and systemic symptoms (DRESS) and toxic epidermal necrolysis (TEN)

            Blood and lymphatic system disorders: Agranulocytosis, eosinophilia

            Previous
            Next:

            Warnings

            Black Box Warnings

            Cardiovascular death

            • Patients with established cardiovascular (CV) disease treated with febuxostat had a higher rate of CV death compared with those treated with allopurinol in a CV outcomes study
            • Evaluate risks and benefits when prescribing febuxostat or continuing treatment

            Contraindications

            Coadministration with azathioprine or mercaptopurine

            Cautions

            After initiation, an increase in gout flares is frequently observed; increase is due to reduction in serum uric acid levels, resulting in mobilization of urate from tissue deposits

            Not tested for secondary hyperuricemia; not recommended in patients whose rate of urate formation is greatly increased (eg, malignant disease and its treatment, Lesch-Nyhan syndrome)

            Postmarketing reports of serious skin and hypersensitivity reactions reported; discontinue if serious skin reactions are suspected; caution in patients who reported previous similar skin reactions to allopurinol

            Postmarketing reports of fatal and nonfatal hepatic failure; may increase liver enzyme activity; obtain LFTs at baseline, and do not initiate if alanine aminotransferase is 3x ULN with total bilirubin >2x ULN

            Serious skin and hypersensitivity reactions, including Stevens-Johnson Syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS) and toxic epidermal necrolysis (TEN) reported; discontinue therapy if serious skin reactions suspected; many patients reported previous similar skin reactions to allopurinol; use caution in these patients

            Cardiovascular death

            • A cardiovascular (CV) outcome study (ClinicalTrials.gov identifier NCT01101035) in patients with a history of major CV disease, cerebrovascular disease, or diabetes mellitus with micro- and/or macrovascular disease showed that febuxostat had a significantly higher incidence of CV deaths compared with allopurinol
            • Most common cause of adjudicated CV deaths in the febuxostat group was sudden cardiac death compared with the allopurinol group; similar results to allopurinol were observed for nonfatal MI, nonfatal stroke, and unstable angina with urgent coronary revascularization (see Black Box Warnings)
            • Because of increased risk of CV death, drug should only be used in patients who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable

            Drug interaction overview

            • Xanthine oxidase substrates
              • Febuxostat inhibits xanthine oxidase (XO)
              • Based on a drug interaction study in healthy patients, febuxostat altered the metabolism of theophylline in humans; caution if coadministered
              • Other drugs that are metabolized by XO (eg, mercaptopurine and azathioprine) have not been conducted; XO inhibition may increase plasma concentrations of these drugs leading to toxicity (see Contraindications)
            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy

            Limited available data in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes

            Animal data

            • No adverse developmental effects observed in embryo-fetal development studies with oral administration of febuxostat to pregnant rats and rabbits during organogenesis at doses that produced maternal exposures up to 40 and 51 times, respectively, the exposure at the maximum recommended human dose (MRHD)
            • No adverse developmental effects observed in a pre- and postnatal development study with administration of febuxostat to pregnant rats from organogenesis through lactation at an exposure ~11 times the MRHD

            Lactation

            There are no data on presence of febuxostat in human milk, effects on breastfed infant, or on milk production; drug is present in rat milk

            Consider the developmental and health benefits of breastfeeding along with mother’s clinical need for therapy and any potential adverse effects on breastfed child from therapy or from underlying maternal condition

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Xanthine oxidase inhibitor; inhibits conversion of hypoxanthine to xanthine to uric acid; at therapeutic dosages, decreases production of uric acid without disrupting synthesis of vital purines and pyrimidines

            Absorption

            Absorption: 49%

            Peak plasma concentration: ~1.6 mcg/mL (40-mg dose); 2.6 mcg/mL (80-mg dose)

            Peak plasma time: 1-1.5 hr

            Following multiple 80 mg qDay doses with a high fat meal, peak plasma concentration decreased by 49% and AUC decreased by 18%

            Distribution

            Protein bound: 99.2%

            Vd: 50 L

            Metabolism

            Metabolized by UGT1A1, UGT1A3, UGT1A9, and UGT2B7; oxidized by CYP1A2, CYP2C8, and CYP2C9; also metabolized by non-CYP450 enzymes

            Elimination

            Half-life: 5-8 hr

            Excretion: Feces (45%; 12% unchanged; 25% their conjugates; 7% other unknown metabolites), urine (49%; 3% unchanged)

            Previous
            Next:

            Administration

            Oral Administration

            Take without regard to food or antacid use

            Storage

            Protect from light

            Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F)

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.